Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 15/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 15/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.54 |
| ▸ | FABP3 | P05413 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494629 | 0.85 | AKR1C3 (0.67) | AKR1C3AKR1C2GAAKDM4EAPAF1 | |
| SCHEMBL10834828 | 0.85 | AKR1C3 (0.67) | AKR1C3AKR1C2GAAKDM4EAPAF1 | |
| SCHEMBL4225648 | 0.85 | AKR1C3 (0.64) | AKR1C3AKR1C2GAA | |
| SCHEMBL4229310 | 0.83 | AKR1C3 (0.74) | AKR1C3AKR1C2PRSS12 | |
| SCHEMBL4223433 | 0.83 | FABP4 (0.58) | AKR1C3AKR1C2KDM4EAPAF1RECQL | |
| SCHEMBL4215380 | 0.82 | AKR1C3 (0.56) | AKR1C3AKR1C2GAA | |
| SCHEMBL4221676 | 0.81 | AKR1C3 (0.78) | AKR1C3AKR1C2 | |
| SCHEMBL30294718 | 0.80 | AKR1C3 (0.63) | AKR1C3AKR1C2 | |
| SCHEMBL22853342 | 0.80 | AKR1C3 (0.63) | AKR1C3AKR1C2 | |
| SCHEMBL10074768 | 0.79 | AKR1C3 (0.73) | AKR1C3AKR1C2KDM4EAPAF1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | AKR1C3 105/4885AKR1C2 287/4885GAA 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.